RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

BACKGROUND: Immune checkpoint inhibitors (ICIs) are highly effective in patients with microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC). Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria may underestimate response to ICIs due to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Romain, Bennouna, Jaafar, Meurisse, Aurélia, Tournigand, Christophe, De La Fouchardière, Christelle, Tougeron, David, Borg, Christophe, Mazard, Thibault, Chibaudel, Benoist, Garcia-Larnicol, Marie-Line, Svrcek, Magali, Vernerey, Dewi, Menu, Yves, André, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640587/
https://www.ncbi.nlm.nih.gov/pubmed/33148693
http://dx.doi.org/10.1136/jitc-2020-001499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640587/
https://www.ncbi.nlm.nih.gov/pubmed/33148693
http://dx.doi.org/10.1136/jitc-2020-001499

Ejemplares similares